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Diabetes is an important cardiovascular risk factor, but until recently there has been a disconnect between 
diabetic management and reduction of cardiovascular mortality and morbidity. Indeed, such was the 
mixed impact of previous generations of anti-hyperglycaemics that the US and European drug regulatory 
bodies mandated cardiovascular outcome studies for all future therapeutic interventions. It is ironic that 
this move has unveiled the unexpected but welcomed benefit of a new generation of diabetic 
management therapies that include the SGLT2 inhibitors.  Much has already been written regarding the 
reduction of cardiovascular death in patients with, or at high risk of developing coronary artery disease 
and much speculation regarding the mechanism of cardioprotection in respect to blood pressure 
reduction, diuresis and weight loss1. However, it is also worth speculating that these drugs have 
additional, potentially pleiotropic effects that underlie their cardioprotective outcomes. 
SGLT2 inhibitors: a class benefit 
With two large clinical outcome studies (Empagliflozin/ EMPA-REG OUTCOME2 and Canagliflozin/ 
CANVAS3) in addition to supporting registry data from the retrospective CVD-REAL study4, it seems 
increasingly likely that the cardiovascular benefit of SGLT2 inhibition is a class effect. Mortality curves 
separate extremely quickly – within the first 2-3 months of treatment initiation, an observation that 
appears to favour a direct, cytoprotective mechanism of action against the toxic effect of elevated glucose 
in stressed cells. Indeed, in the high-risk patient cohort examined in the EMPA-REG study, patients were 
just as likely to suffer an acute myocardial or cerebral ischaemic event on an SGLT2 inhibitor, but they had 
a better chance of surviving that event – an observation supportive of a cellular protective hypothesis in 
the setting of an acute injury.  
Potential cytoprotective mechanisms  
There is emerging evidence of at least four disparate pleiotropic effects of SGLT2 inhibitors that extend 
beyond their efficacy as oral anti-hyperglycaemics, impacting upon tissues (brain and heart) that have 
negligible native SGLT2 expression.  
1) The interaction between SGLT1/SMIT and gp91phox NADPH oxidase  
Reactive oxygen species (ROS) play a highly regulated role in normal physiological signalling and are 
involved in cellular adaptions to cellular stress (for example, gp91phox NADPH oxidase-linked ischaemic 
conditioning5). However, excess ROS production leads to pathological states such as heart failure and 
exacerbation of ischaemic cell death as occurs in ischaemia/reperfusion injury and heart failure.6 In the 
heart, SGLT1/SMIT has been linked gp91phox NADPH oxidase activity7, and demonstrated as a cause of 
myocardial injury. Clinical SGLT2 inhibitors such as Empagliflozin are highly selective towards SGLT2, but 
others, such as Canagliflozin, have more mixed SGLT2/SGLT1 inhibitory action; SGLT1 inhibition abrogates 
the excess ROS generation precipitated by pathophysiologically-relevant high glucose in experimental 
models7, and thus raises the hypothesis that SGLT2 inhibitors, either directly through mixed SGLT2/SGLT1 
inhibition, or indirectly through improved glycaemic control at the time of the ischaemic insult, may 
reduce injury through attenuation of oxidant stress in ischaemic tissue. 
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2) Inhibition of the sodium hydrogen exchanger (NHE) 
Recent data from Zuurbier’s group demonstrates that Empagliflozin, at a clinically relevant concentration, 
attenuates myocyte sodium accumulation associated with raised extracellular glucose via NHE inhibition. 
The subsequent attenuation of cytosolic calcium accumulation and increased mitochondrial calcium8 is 
beneficial in heart failure.9  Moreover, NHE inhibition is known to be cardioprotective in the context of 
ischaemia/reperfusion injury: in animal studies, NHE inhibition has been found to be highly effective at 
reducing myocardial injury. These data informed early clinical trials studying acute NHE-1 inhibition in the 
context of ACS and CABG. However, these studies (ESCAMI and GUARDIAN) were largely neutral, thought 
to be due to failure of the inhibitors to reach the ischaemic myocardium prior to revascularisation; in 
animal studies, these drugs were highly cardioprotective only when administered prior to the onset of 
injurious ischaemia.10 While it is not known whether other SGLT2 inhibitors share this NHE inhibitory 
potential, patients in the EMPA-REG study would already have been exposed to Empagliflozin-mediated 
NHE inhibition prior to the ischaemic insult, raising an interesting, testable hypothesis to explain the 
observed reduction of fatal myocardial and cerebral ischaemia through NHE inhibition.  
3) Inhibition of SGLT-induced intracellular sodium and calcium accumulation 
In a similar vein to (1) and (2) above, a “glucotoxicity” model of exacerbated cellular injury has been 
suggested based upon neuronal and myocardial SGLT1 activity. Increased extracellular glucose promotes 
sodium and glucose transport into cells, and in the context of acute ischaemia/ reperfusion injury – as 
occurs in myocardial infarction or stroke – the combination of elevated extracellular glucose and 
vulnerable, post-ischaemic cells leads to toxic accumulation of sodium and therefore also of calcium, 
which in turn leads to opening of the mitochondrial permeability transition pore and thus to cell death.11  
That SGLT1 expression is also increased following ischaemia and in heart failure, SGLT1 may therefore play 
an important role in exacerbating cellular injury. While highly selective clinical SGLT2 inhibitors will have 
minimal impact upon SGLT1 activity, we hypothesise that improved glucose control with missed 
SGLT1/SGLT2 inhibitors may themselves be sufficient to mitigate against SGLT1-mediated glucotoxicity in 
acutely injured cells.  
4) Glucagon and metabolic substrate switching towards ketones  
Change of myocardial energy utilisation and metabolic substrate switching may not be unique to SGLT2 
inhibitors, but these drugs do lead to marked glycosuria, caloric loss and a mild ketogenesis in diabetic 
patients.12 Glucagon release by pancreatic -cells is increased following SGLT2 inhibition, which may be 
beneficial in heart failure through its ionotropic effects,13 but also increases availability of circulating 
ketones, thereby providing organs that are critically challenged by hypoxia or ischaemia are provided with 
an advantageous energy substrate in which to synthesise ATP with reduced oxygen consumption as 
compared to glucose or fat, as postulated by Ferrannini and others.14,15 Very little experimental data is 
currently available to support this hypothesis as an explanation for the advantageous outcomes in EMPA-
REG and CANVAS, but it presents an intriguing avenue for further exploration. 
Summary and conclusions 
The recent outcome studies, EMPA-REG and CANVAS, present a dramatic step-change in our 
understanding of the management of diabetes and cardiovascular disease. Unexpected and welcome, 
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SGLT2 inhibition has been shown to have a beneficial cardiovascular outcome in patients with type 2 
diabetes. While questions still remain, we are at an exciting juncture where anti-hyperglycaemic therapies 
may finally realise cardiovascular benefits in patients with type 2 diabetes. Oddly perhaps, we now need 
to undertake reverse translational medicine – i.e from bed-side to bench - and start to work out how these 
exciting findings are manifest 
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